Dr. Steven R. Goldstein: Medications by Top Obgyn in Manhattan help with Breast Cancer & Bone Loss Prevention

Dr. Steven R. Goldstein MD is an expert obgyn in Manhattan, considered one of the nation’s top doctors in gynecology. In private practice for over 25 years, Dr. Goldstein has had patients who were excellent candidates for Evista (raloxifene) because of its dual effect of reducing breast cancer risk and preventing and treating osteoporosis.

Tamoxifen, raloxifene (also known as Evista) have been been shown to reduce breast cancer risk. Aromotase inhibitors are also, but they are not the focus of this article.

Tamoxifen is the only one approved for use in premenopausal women. Many of you are aware, however, that it results in formation of benign uterine polyps in 10-17% of women as well as a small but real number of uterine cancers in postmenopausal women. Evista, which is now generically available as raloxifene, has similar breast cancer prevention results as tamoxifen but does not have cancer or polyp producing potential in the uterus.

In addition, however, both tamoxifen and raloxifene prevent bone loss because of their selectivity in which they act like estrogen in bone, while being estrogen blockers in breast.

Since early detection of breast cancer will almost always result in a favorable outcome, and since women are routinely living much longer lives than previous generations, a fracture, especially of the hip, of a woman can be a much more life threatening and devastating event than an early breast cancer.

Thus Evista (raloxifene) because of its dual effect of reducing breast cancer risk and preventing and treating osteoporosis, remains an excellent choice for some patients.

To find out more about Dr. Steven R. Goldstein MD, an expert obgyn in Manhattan, or schedule an appointment to discuss your gynecological conditions, visit www.goldsteinmd.com.